Show simple item record
Author | dc.contributor.author | Wolfe, G. I. | |
Author | dc.contributor.author | Kaminski, H. J. | |
Author | dc.contributor.author | Aban, I. B. | |
Author | dc.contributor.author | Minisman, G. | |
Author | dc.contributor.author | Kuo, H. C. | |
Author | dc.contributor.author | Marx, A. | |
Author | dc.contributor.author | Ströbel, P. | |
Author | dc.contributor.author | Mazia, C. | |
Author | dc.contributor.author | Oger, J. | |
Author | dc.contributor.author | Cea, J. G. | |
Author | dc.contributor.author | Heckmann, J. M. | |
Author | dc.contributor.author | Evoli, A. | |
Author | dc.contributor.author | Nix, W. | |
Author | dc.contributor.author | Ciafaloni, E. | |
Author | dc.contributor.author | Antonini, G. | |
Author | dc.contributor.author | Witoonpanich, R. | |
Author | dc.contributor.author | King, J. O. | |
Author | dc.contributor.author | Beydoun, S. R. | |
Author | dc.contributor.author | Chalk, C. H. | |
Author | dc.contributor.author | Barboi, A. C. | |
Author | dc.contributor.author | Amato, | |
Admission date | dc.date.accessioned | 2019-03-18T11:54:54Z | |
Available date | dc.date.available | 2019-03-18T11:54:54Z | |
Publication date | dc.date.issued | 2016 | |
Cita de ítem | dc.identifier.citation | New England Journal of Medicine, Volumen 375, Issue 6, 2018, Pages 511-522 | |
Identifier | dc.identifier.issn | 15334406 | |
Identifier | dc.identifier.issn | 00284793 | |
Identifier | dc.identifier.other | 10.1056/NEJMoa1602489 | |
Identifier | dc.identifier.uri | https://repositorio.uchile.cl/handle/2250/166871 | |
Abstract | dc.description.abstract | Copyright © 2016 Massachusetts Medical Society. BACKGROUND: Thymectomy has been a mainstay in the treatment of myasthenia gravis, but there is no conclusive evidence of its benefit. We conducted a multicenter, randomized trial comparing thymectomy plus prednisone with prednisone alone. METHODS: We compared extended transsternal thymectomy plus alternate-day prednisone with alternate-day prednisone alone. Patients 18 to 65 years of age who had generalized nonthymomatous myasthenia gravis with a disease duration of less than 5 years were included if they had Myasthenia Gravis Foundation of America clinical class II to IV disease (on a scale from I to V, with higher classes indicating more severe disease) and elevated circulating concentrations of acetylcholine-receptor antibody. The primary outcomes were the time-weighted average Quantitative Myasthenia Gravis score (on a scale from 0 to 39, with higher scores indicating more severe disease) over a 3-year period, as assessed by means of | |
Lenguage | dc.language.iso | en | |
Publisher | dc.publisher | Massachussetts Medical Society | |
Type of license | dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Chile | |
Link to License | dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/cl/ | |
Source | dc.source | New England Journal of Medicine | |
Keywords | dc.subject | Medicine (all) | |
Título | dc.title | Randomized trial of thymectomy in myasthenia gravis | |
Document type | dc.type | Artículo de revista | |
dcterms.accessRights | dcterms.accessRights | Acceso Abierto | |
Cataloguer | uchile.catalogador | SCOPUS | |
Indexation | uchile.index | Artículo de publicación SCOPUS | |
uchile.cosecha | uchile.cosecha | SI | |
Files in this item
- Name:
- nejmoa1602489.pdf
- Size:
- 506.7Kb
- Format:
- PDF
This item appears in the following Collection(s)
Show simple item record
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile